Phthalazine compounds as p38 map kinase modulators and methods of use thereof
    5.
    发明授权
    Phthalazine compounds as p38 map kinase modulators and methods of use thereof 有权
    酞嗪化合物作为p38映射激酶调节剂及其使用方法

    公开(公告)号:US08497269B2

    公开(公告)日:2013-07-30

    申请号:US13123889

    申请日:2009-10-07

    摘要: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A4, L, R1, R2, R3, R5 and m are as defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, ankylosing spondylitis, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

    摘要翻译: 本发明包括一类新的可用于预防和治疗蛋白激酶介导的疾病,包括炎症和相关病症的化合物。 该化合物具有通式I,其中A4,L,R1,R2,R3,R5和m如本文所定义。 本发明还包括药物组合物,其包含一种或多种式I化合物,用于治疗p38地图激酶介导的疾病包括类风湿性关节炎,牛皮癣,慢性阻塞性肺病,强直性脊柱炎,疼痛和其它炎症性疾病的化合物和组合物的用途,如 以及可用于制备式I化合物的中间体和方法。